Compound Guide

BPC-157

BPC-157 after the April 15 FDA reclassification — the research base, safety signals, expected compounded pricing, and how to source it through a real pharmacy.

Last reviewed April 23, 2026

Quick Summary

What it is. Body Protection Compound 157 — a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice.

Most-studied uses. Soft-tissue injury recovery, tendon and ligament repair, inflammatory bowel conditions, joint pain.

Current U.S. legal status (April 2026). On April 15, 2026, the FDA removed BPC-157 from Category 2. It is now on an interim evaluation tier pending final 503A Bulks List placement at the July 23–24, 2026 PCAC meeting. Licensed compounding pharmacies may legally fill prescriptions.

Expected post-PCAC compounded price. $100–$200 per 5mg vial at a legitimate compounding pharmacy.

Evidence base. Extensive preclinical (animal-model) research. Human clinical trial data is limited. Widely used in the practitioner community under off-label supervision.

What is BPC-157?

BPC-157 — short for Body Protection Compound 157 — is a synthetic peptide consisting of 15 amino acids in a specific sequence (GEPPPGKPADDAGLV). It was originally identified as a stable fragment of a larger protective protein found in human gastric juice, and has been studied since the early 1990s, most extensively by research groups in Croatia.

The peptide’s name reflects its proposed mechanism: body protection. In preclinical models, BPC-157 has demonstrated effects on tissue repair across multiple tissue types — muscle, tendon, ligament, bone, gastrointestinal mucosa, and vascular endothelium — through mechanisms that include modulation of nitric oxide signaling, stimulation of angiogenesis (new blood vessel formation), and interaction with growth factor pathways.

Unlike many of the other peptides reclassified on April 15, BPC-157 does not precisely mimic a naturally occurring human signaling molecule. It is a stable synthetic construct designed to survive gastric conditions, which is part of why oral administration has been studied alongside injectable routes.

What the Research Shows

Preclinical evidence is extensive

Published preclinical research — predominantly in rodents — suggests BPC-157 can accelerate healing across several tissue types:

Tendon and ligament. Multiple rat-model studies of Achilles tendon and medial collateral ligament transection healing show faster functional recovery and improved tissue organization with BPC-157 administration.
Gastrointestinal. Studies of chemically induced colitis, gastric ulceration, and gut mucosal damage show accelerated healing.
Muscle. Crush-injury and denervation models show muscle fiber preservation and faster functional recovery.
Nervous system. Peripheral nerve transection models and some CNS injury models show neuroregenerative effects.
Cardiovascular. Studies of drug-induced cardiac injury models show cardioprotective effects.

The breadth of these findings is striking, and is part of why BPC-157 has attracted so much practitioner attention. It is also a reason to remain cautious: peptides that appear to “do everything” in animal models often show narrower effects when tested rigorously in humans.

Human clinical data is limited

As of April 2026, published large-scale randomized controlled trial data for BPC-157 in humans is effectively absent. This is the single most important qualifier in any honest assessment of the peptide.

What does exist in the human-facing literature includes small observational and practitioner case series, early-phase trials of related formulations for specific indications (published primarily by the Croatian research groups), and extensive anecdotal reporting from practitioner networks, sports medicine, and regenerative medicine clinics.

The practitioner experience with BPC-157 has been broadly positive, which is a meaningful signal but not a substitute for controlled human evidence. The FDA’s reclassification on April 15 does not resolve this — it opens access; it does not endorse efficacy.

Where BPC-157 is most commonly prescribed

In the practitioner community, BPC-157 is most frequently prescribed for chronic tendinopathy (Achilles, rotator cuff, patellar, tennis/golfer’s elbow) that has not responded to conventional first-line management, post-surgical soft-tissue recovery as an adjunct to standard rehabilitation, inflammatory bowel conditions typically as an adjunct to standard therapy under gastroenterology supervision, and joint pain with imaging-confirmed inflammatory or structural contribution.

It is less commonly indicated for goals like general “wellness,” fatigue, or unspecified “recovery” — and prescribers who treat it as a first-line intervention for such goals are out of step with the practitioner consensus.

Legal and Regulatory Status

Pre-April 15, 2026

Prior to the April 15 reclassification, BPC-157 was listed in Category 2 of the FDA’s 503A compounding evaluation framework. In practical terms, this meant licensed compounding pharmacies could not compound BPC-157 at scale without drawing regulatory attention. Patient-specific compounding occurred in narrow circumstances; most consumer access came through the gray-market “research chemical” channel.

April 15, 2026 — Reclassification

On April 15, 2026, the FDA removed BPC-157, along with 11 other peptides, from Category 2 and placed it on an interim evaluation tier. Licensed compounding pharmacies may now legally prepare BPC-157 under a valid prescription. The FDA has committed to a final 503A Bulks List placement decision at the July 23–24, 2026 PCAC meeting.

July 23–24, 2026 — PCAC Outlook

The Pharmacy Compounding Advisory Committee’s July 2026 meeting will recommend final placement for BPC-157. Industry expectation, based on the peptide’s extensive preclinical evidence base and clean practitioner safety profile, is that BPC-157 is among the most likely of the 12 reclassified peptides to receive clean approval without restrictions.

We will update this page within 72 hours of the PCAC outcome. Subscribers to the PeptidesBeat Daily Brief receive regulatory updates in real time.

State-level variance

Federal reclassification sets the floor; state pharmacy boards can set tighter rules. California, New York, Massachusetts, Connecticut, Illinois, Maryland, New Jersey, Hawaii, Vermont, and DC maintain more restrictive non-resident pharmacy regimes — expect extra verification steps in those states. See the state-by-state tracker for your jurisdiction.

The research-chemical channel remains outside the law

The April 15 action clarifies the prescription pathway. It does not legitimize the gray market. BPC-157 purchased from a research-chemical vendor labeled “not for human consumption” is still operating outside the legal drug supply chain — regardless of the federal reclassification. Customs enforcement of imports has tightened visibly in 2025–2026.

How It’s Typically Administered

Important: Nothing below is a dosing recommendation. Route of administration, dose, frequency, and duration are prescriber-determined. This section describes what practitioners report as typical practice, not what you should do.

BPC-157 is most commonly administered by one of three routes — subcutaneous injection (the most common route in U.S. practitioner use, small-volume injections typically administered at or near the site of injury or systemically), intramuscular injection (sometimes used, particularly for larger muscle-group injuries), and oral administration (less commonly prescribed; BPC-157 is reported to retain some activity after oral administration due to its stability in gastric conditions, though bioavailability data is limited).

A typical practitioner-prescribed course lasts 2–6 weeks, followed by a break. Extended continuous use is not the standard protocol; limited courses with break intervals are.

Reported Safety Signals

Across preclinical animal models and the practitioner human literature, BPC-157 has an unusually clean reported short-term safety profile. Serious adverse events are rarely reported.

Reported mild adverse events include local injection-site reactions (redness, soreness), transient fatigue on initial administration, and mild gastrointestinal upset with oral administration.

Theoretical concerns that have been raised but not definitively established include effects on angiogenesis in the context of occult malignancy. This is the reason experienced prescribers typically screen for active or recent cancer history before prescribing BPC-157 for any indication.

Long-term human safety data is effectively absent. This is the honest truth about the entire practitioner-peptide category: short-term practitioner experience looks favorable; long-term outcome data in humans has not been systematically collected. Proceed under licensed practitioner supervision; disclose your full medical history; follow your prescriber’s monitoring recommendations.

Expected Pricing (Post-PCAC)

Format	Expected price range
5mg vial (lyophilized, for reconstitution)	$100–$200
5mg vial (reconstituted, ready-to-use)	$140–$240
10mg vial	$180–$320
Combination BPC-157/TB-500 (standard)	$180–$300 per 5mg/5mg vial
Oral capsules (30-day supply)	$120–$220

Research-chemical vendors price 30–50% lower than these ranges. That price delta is not a savings — it reflects the absence of sterility testing, potency verification, third-party COAs, and pharmacist oversight. Independent testing of gray-market peptides has historically shown contamination rates between 20% and 60%, including bacterial endotoxin levels that can cause serious harm.

How to Source It Legitimately

The prescription pathway, step by step:

Establish a relationship with a peptide-familiar prescriber. This can be an MD, DO, NP, or PA, depending on state regulations. See our peptide-familiar prescriber directory. Telehealth is acceptable in most permissive and moderate-tier states; confirm eligibility with the prescriber before booking.
Have a documented clinical reason. Licensed prescribers need a clinical basis for the prescription. “I want to try peptides” is not a clinical basis. “I have a chronic Achilles tendinopathy that hasn’t responded to 6 months of PT and is limiting my training” is. Bring records if you have them.
Identify a legitimate compounding pharmacy licensed in your state. Use our vetted compounding pharmacy directory. Confirm the pharmacy holds current licensure in both its home state and yours. Apply the 10-point pharmacy checklist before placing an order.
Request a Certificate of Analysis for your specific batch, not a generic example. A legitimate compounder provides this without hesitation.
Verify shipping and cold-chain. BPC-157 should ship with cold packs. A package that arrives warm has been compromised.
Maintain your supervision relationship. Follow your prescriber’s check-in protocol. Report any unexpected symptoms.

This path is slower and slightly more expensive than the gray market. It is also the only path that is legal, verifiable, and integrated with the rest of your medical care.

Common Questions

Is BPC-157 FDA approved?

No. BPC-157 is not an FDA-approved drug for any indication. The April 15, 2026 action removed it from Category 2 (prohibited for compounding), which allows licensed compounding pharmacies to prepare it under prescription. This is a different regulatory status than FDA approval, which requires demonstrated safety and efficacy in large human clinical trials.

Is BPC-157 legal in my state?

Federal reclassification permits compounding nationwide, but state pharmacy board rules vary. Ten states and DC maintain more restrictive regimes that add verification steps. See our state-by-state tracker for your specific jurisdiction.

Is BPC-157 safe?

The short-term reported safety profile is favorable in both animal research and practitioner human use. Long-term human safety data is limited. Standard practice is supervision by a licensed clinician who has screened for contraindications (active malignancy, specific conditions) and who monitors the course.

Can I buy BPC-157 online without a prescription?

You can find online vendors selling BPC-157 as a “research chemical.” This path is not legal for human use, frequently supplies contaminated or underpotent product, and leaves you without a clinician of record. We actively recommend against it. The legal path is prescription + compounding pharmacy.

How long does BPC-157 take to work?

Practitioner reports typically describe onset of effect within 1–3 weeks for soft-tissue indications, with most reported benefit emerging over 3–6 weeks. Courses longer than 8 weeks are not standard practice.

BPC-157 vs TB-500 — which should I use?

They are complementary, not interchangeable. BPC-157 is thought to act more locally at the tissue level; TB-500 acts more systemically on cellular migration and repair signaling. Many practitioners prescribe them in combination for soft-tissue injury. Some use one or the other alone. The decision is indication-specific. See our TB-500 pillar.

What are the side effects of BPC-157?

Reported side effects are typically mild and include local injection-site reactions, transient fatigue, and mild GI upset with oral administration. Serious adverse events are rarely reported, though the total human exposure data is modest. Theoretical concerns around angiogenesis in the setting of occult malignancy are the reason experienced prescribers screen for cancer history before prescribing.

What’s the right dose of BPC-157?

Dosing is prescriber-determined. Routes of administration, amounts, and schedules vary meaningfully depending on indication, body size, and clinical goals. We do not publish dosing protocols — it is the single most important reason to work with a licensed prescriber rather than a forum.

Does BPC-157 show up on drug tests?

BPC-157 is not included on standard employment or athletic drug screens. However, it may be captured by specialized sports-anti-doping testing in the future, and any peptide is potentially identifiable with targeted mass spectrometry. WADA-affiliated athletes should assume BPC-157 use carries sport-specific risk regardless of test screening panels.

Where should I start if I’m considering BPC-157?

Three steps. First, read the 2026 Peptide Law Playbook for the full context. Second, find a peptide-familiar prescriber in your state through our provider directory. Third, apply the 10-point pharmacy checklist before placing any order. In that order.

TB-500 — Commonly paired with BPC-157 for soft-tissue and recovery indications.
KPV — Considered alongside BPC-157 for GI-inflammatory indications.